POC Breast 1 | 2007 - Adjuvant Trastuzumab
First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone.
Taxotere 20 Mg
Neoplasie del Colon-retto.
Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.
There is more to clinical trials than chemotherapy and survival Alan P. Venook, M.D. University of California, SF.
Abstract 8504: E4697: Phase III Cooperative Group Study of Yeast Derived GM-CSF vs Placebo as Adjuvant Treatment of Patients with Completely Resected Stage.
Abstract Introduction What is a Herceptin (Trastuzumab) ? Herceptin (Trastuzumab) is an monoclonal antibody,it is an example of targeted therapy an.
FACULTY DISCLOSURES - DJS Advisory Boards: BioMarin, Genentech/Roche, Pfizer, Novartis, Stock: Amgen, Pfizer, BioMarin San Antonio Breast Cancer Symposium,
Emerging Trends in Biosimilars and Biologics Prof. Dr. Kaiser Jamil Bhagwan Mahavir Medical Research Centre, Hyderabad -TS E-mail: [email protected]@gmail.com.
November 2011, Vol 2, No 6
Presented By Eric Winer at 2014 ASCO Annual Meeting
